A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

Cancer Research

Volumn 69, Issue 6, 2009, Pages 2305-2313

  Guo, Zhiyong ^a   Yang, Xi ^a   Sun, Feng ^a   Jiang, Richeng ^a   Linn, Douglas E ^a   Chen, Hege ^a   Chen, Hegang ^b   Kong, Xiangtian ^c   Melamed, Jonathan ^c   Tepper, Clifford G ^d   Kung, Hsing Jien ^d   Brodie, Angela M H ^a   Edwards, Joanne ^e   Qiu, Yun ^a,b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR 3; ANDROGEN RECEPTOR 4; ANDROGEN RECEPTOR 5; UNCLASSIFIED DRUG; ISOPROTEIN; PROTEIN KINASE B;

ARTICLE; BINDING SITE; CANCER CELL; CANCER GROWTH; CANCER RISK; CELL CULTURE; CONTROLLED STUDY; DEPLETION; HORMONE RESISTANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN VARIANT; RECEPTOR UPREGULATION; RECURRENCE RISK; TISSUE MICROARRAY; XENOGRAFT; ANIMAL; BIOSYNTHESIS; CELL GROWTH; CELL STRAIN COS1; CERCOPITHECUS; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR CLONING; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR RECURRENCE; UPREGULATION;

ANDROGENS; ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CLONING, MOLECULAR; COS CELLS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; UP-REGULATION;

EID: 65549168746     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3795     Document Type: Article

References (45)

1. Denmeade SR, Isaacs JT, A history of prostate cancer treatment. Mat Rev Cancer 2002;2:389-96.
2. Litvinov IV, Antony L, Isaacs JT. Molecular characterization of an improved vector for evaluation of the tumor suppressor versus oncogene abilities of the androgen receptor. Prostate 2004;61:299-304.
3. Feldman Bj, Feldman D. The development of androgen- independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
4. Dehes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. K Engl J Med 2004;351:1488-90.
5. Chang CS, Kokontis J, Liao ST. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988;240:324-6.
6. Lubahn DB, Joseph DR, Sar M, et al. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol 1988;2:1265-75.
7. McPhaul MJ. Factors that mediate and modulate androgen action.J Investig Dermatol Symp Proc 2003;8:1-5.
8. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
9. Kuiper GG, Faber PW, van Rooij HC, et al. Structural organization of the human androgen receptor gene. J Mol Endocrinol 1989;2:Rl-4.
10. Lubahn DB, Brown TR, Simental JA, et al. Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc Natl Acad Sci U S A 1989;86:9534-8.
11. Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Rung HJ, Mudryj M. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res 2007;67:9001-5.
12. Simental JA, Sar M, Lane MV, French FS, Wilson EM. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991;266: 510-8.
13. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman j, Brinkmann AO. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 1991;5:1396-404.
14. Rundlett SE, Wu XP, Miesfeld RL. Functional characterizations of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation. Mol Endocrinol 1990;4:708-14.
15. Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H, Yam am o to KR. Cell- and gene-specific regulation of primary' target genes by the androgen receptor. Genes Dev 2007;21:2005-17.
16. Wang Q, Li W, Liu XS, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007;27:380-92.
17. Marcelli M, Cunningham GR. Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metah 1999;84:3463-8.
18. Culig Z, Klocker H, Bartsch G, Hobisch A. Androgen receptors in prostate cancer. Endocr Relat Cancer 2002; 9:155-70.
19. Chen CD, Welshie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
20. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62:1008-13.
21. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 1999;96:5458-63.
22. Ling MT, Chan KW, Choo CK. Androgen induces differentiation of a human papillomavirus 16 E6/E7 immortalized prostate epithelial cell line, j Endocrinol 2001;170:287-96.
23. Lin HR, Hu YC, Yang L, et al. Suppression versus induction of androgen receptor functions by the phosphatidyl inositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers, j Biol Chem 2003;278:50902-7.
24. Gregory CW, Fei X, Ponguta LA, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004; 279:7119-30.
25. Ueda T, Mawji KR, Bruchovsky N, Sadar MD. Ligand- independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells, j Biol Chem 2002;277: 38087-94.
26. Guo Z, Dai B, Jiang T, et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006;10:309-19;
27. Mahajan NP, Liu Y, Majumder S, et al. Activated Cdc42-associated kinase Ackl promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci USA 2007;104:8438-43.
28. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001-15.
29. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653-7.
30. Tepper CG, Boucher DL, Ryan PE, et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002;62:6606-14.
31. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance. Cancer Res 2008;68:5469-77.
32. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF. Establishment and characterization of androgen- independent human prostate cancer LNCaP cell model. Prostate 2002;50:222-35.
33. Gregory CW, Johnson KT, Jr., Mohler JL, French PS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61:2892-8.
34. Zhang Y, Wang XW, Jelovac D, et al. The ErbB3-binding protein Ebpl suppresses androgen receptor- mediated gene transcription and tumorigenesis of prostate cancer cells. Proc Natl Acad Sci U S A 2005; 102:9890-5.
35. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
36. Gregory CW, He B, Wilson EM. The putative androgen receptor-A form results from in vitro proteolysis. J Mol Endocrinol 2001;27:309-19.
37. Best CJ, Gillespie JW, Yi Y, et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005;11:6823-34.
38. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8:393-406.
39. Chen ML, Xu PZ, Peng XD, et al. The deficiency of Aktl is sufficient to suppress tumor development in Pten+/- mice. Genes Dev 2006;20:1569-74.
40. Johansson A, Jones J, Pietras K, et al. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model. Prostate 2007;67:1664-76.
41. Cunha GR, Cooke PS, Kurita T. Role of stromal- epithelial interactions in hormonal responses. Arch Histol Cytol 2004;67:417-34.
42. Kurita T, Wang YZ, Donjacour AA, et al. Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 2001; 8:192-200.
43. English HE, Santen Rj, Isaacs JT. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 1987;11:229-42.
44. Nanni S, Priolo C, Grasselli A, et al. Epithelial- restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res 2006;4:79-92.
45. Le Page C, Koumakpayi IH, Alam-Fahmy M, Mes-Masson AM, Saad F. Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer 2006;94:1906-12.